Les informations fournies sur EL7.AI sont uniquement à des fins éducatives et informatives et ne constituent pas un conseil financier.

Urgentstocks

Ascendis Pharma Reports Positive Two-Year Data for Achondroplasia Treatment

Détecté pour la première fois: Mar 16, 2026, 12:19 PM

Dernière mise à jour: 9 days ago

16 articles·16 articles

Instruments affectés

ASND

Résumé de l'événement

Ascendis Pharma reported positive two-year data for achondroplasia treatment. Data from the ApproaCH trial showed consistent growth improvement in children with achondroplasia using TransCon CNP. Further improvement in body proportionality was observed during the second year of weekly treatment.

Chronologie

Japan Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid

Mar 24, 2026, 6:16 AMImpact: 6

Anavex Life Sciences Reports Positive Long-Term Data for Alzheimer's Treatment

Mar 23, 2026, 11:49 AMImpact: 6

BridgeBio Pharma to Present Long-Term Acoramidis Data at ACC Scientific Sessions

Mar 23, 2026, 11:49 AMImpact: 6

Insmed Reports Positive Phase 3 Results for ARIKAYCE Lung Disease Treatment

Mar 23, 2026, 11:24 AMImpact: 8

Ocugen Reports Positive 12-Month Phase 2 Data for OCU410 Gene Therapy

Mar 23, 2026, 11:17 AMImpact: 6

Vaxcyte Announces Publication of Positive Phase 1/2 Data for VAX-31 Vaccine in The Lancet

Mar 18, 2026, 11:46 PMImpact: 6